The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

A little weight gain during the menopause is normal, but when it happens to a generation who came of age in the skinny-chic ...

Paul Curran, MPharm, a clinical pharmacist with Optimal You in the UK, says there is one nasty side effect, in particular, ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Wegovy, which was approved in 2021 for obesity, contains the same key ingredient as Ozempic, called semaglutide, while Mounjaro uses a slightly different one, tirzepatide.

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...